aTyr Pharma, Inc. (ATYR)

NASDAQ: ATYR · Real-Time Price · USD
3.130
-0.130 (-3.99%)
At close: Mar 28, 2025, 4:00 PM
3.187
+0.057 (1.83%)
After-hours: Mar 28, 2025, 7:59 PM EDT
-3.99%
Market Cap 278.13M
Revenue (ttm) 235,000
Net Income (ttm) -64.02M
Shares Out 88.86M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,129,749
Open 3.250
Previous Close 3.260
Day's Range 3.070 - 3.260
52-Week Range 1.420 - 4.660
Beta 0.99
Analysts Strong Buy
Price Target 18.60 (+494.25%)
Earnings Date Mar 13, 2025

About ATYR

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a do... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2015
Employees 59
Stock Exchange NASDAQ
Ticker Symbol ATYR
Full Company Profile

Financial Performance

In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ATYR stock is "Strong Buy." The 12-month stock price forecast is $18.6, which is an increase of 494.25% from the latest price.

Price Target
$18.6
(494.25% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

1 day ago - GlobeNewsWire

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

3 days ago - GlobeNewsWire

aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating

aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise ...

14 days ago - Seeking Alpha

aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript

aTyr Pharma, Inc. (NASDAQ:ATYR) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Ashlee Dunston - Senior Director of Investor Relations and Public Affairs Sanjay Shukla...

15 days ago - Seeking Alpha

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforc...

15 days ago - GlobeNewsWire

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

Peer-reviewed publication validates efzofitimod's unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) receptor. Scientific insights further strengthen the rationale...

16 days ago - GlobeNewsWire

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

22 days ago - GlobeNewsWire

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro...

25 days ago - GlobeNewsWire

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...

4 weeks ago - GlobeNewsWire

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025

2 months ago - GlobeNewsWire

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

3 months ago - GlobeNewsWire

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

3 months ago - GlobeNewsWire

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

4 months ago - GlobeNewsWire

aTyr Pharma: The Bull Has Finally Come Out

aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without immune...

5 months ago - Seeking Alpha

aTyr Pharma to Present at the LD Micro Main Event XVII in October

San Diego, California--(Newsfile Corp. - October 14, 2024) - aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicin...

5 months ago - Newsfile Corp

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to rea...

7 months ago - Seeking Alpha

aTyr Pharma to Participate in September Investor Conferences

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...

7 months ago - GlobeNewsWire

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second qua...

8 months ago - GlobeNewsWire

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

10 months ago - GlobeNewsWire

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class ...

11 months ago - GlobeNewsWire

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod.

11 months ago - GlobeNewsWire

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents...

11 months ago - GlobeNewsWire

aTyr Pharma to Participate in April Investor Conferences

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro...

1 year ago - GlobeNewsWire

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), all...

1 year ago - GlobeNewsWire